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Five new oxoprotoberberine alkaloids, miliusacunines A-E (1-5), along with nine known 
compounds, 6-14, were isolated from an acetone extract of the leaves and twigs of Miliusa 
cuneata. Their structures were elucidated by spectroscopic analysis. All isolated compounds 
were evaluated for their cytotoxicities against the KB and Vero cell lines and for antimalarial 
activities against the P. falciparum strains TM4 and K1 (a sensitive and a multidrug-resistant 
strain, respectively). Compound 1 showed in vitro antimalarial activity against the TM4 
strain, with an IC50 value of 19.3  3.4 μM, and compound 2 demonstrated significant activity 
against the K1 strain, with an IC50 value of 10.8  4.1 μM. Both compounds showed no 
discernible cytotoxicity to the Vero cell line at the concentration levels evaluated. 
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The plant genus Miliusa (Annonaceae) comprises about 50 species and is distributed from the 
Indian subcontinent to Indochina, Peninsula Malaysia, the Southeast Asian islands, to New 
Guinea and northern Australia.1 Some species have been utilized in traditional medicine, and, 
for example, M. velutina has been used as a tonic and aphrodisiac2 and M. balansae for 
gastropathy and glomerulonephropathy.3 The plants from this genus are reported to contain 
secondary metabolites inclusive of alkaloids,4-6 acetogenins,7 homogentisic acid derivatives,8-
10 flavonoids,5,8-13 dihydrochalcones,5,8 neolignans and lignans,14,15 and terpenoids.5 Several of 
these chemical constituents exhibited antibacterial,7 cytotoxic5,7,12-15 and antiherpetic14,15 
activities.  
Miliusa cuneata Craib is known locally in Thailand as “Ra-Khang-Khieo”. Recently, 
two new isoquinoline alkaloids and thirteen known alkaloids were isolated from the stems 
and leaves of M. cuneata.4 Herein are reported the isolation and structure elucidation of five 
new oxoprotoberberines, miliusacunines A-E (1-5), together with nine known compounds (6-
14), from an acetone extract of the leaves and twigs of M. cuneata as well as an evaluation of 
their in vitro biological activities against the P. falciparum strains TM4 and K1 and the 
human oral epidermal carcinoma (KB) cell line. 
RESULTS AND DISCUSSION 
Column chromatographic separation of an acetone extract of the leaves of M. cuneata 
afforded five new alkaloids, miliusacunines A-E (1-5), along with five known compounds, 
namely, 5-hydroxy-3,7-dimethoxy-3′,4′-methylenedioxyflavone (6),16 pachypodol (7),12,17 4'-
hydroxy-3,5,7,3′-tetramethoxyflavone (8),18 (+)-miliusol (9),10 and (+)-syringaresinol (10).19 
Also, an acetone extract of the twigs of M. cuneata was subjected to column chromatography 
over silica gel and Sephadex LH-20 to provide six known substances, compounds 6 and 7, 
and chrysoplenetin (11),17 N-trans-feruloyltyramine (12),20 N-trans-caffeoyltyramine (13),21 
and N-trans-coumaroyltyramine (14).20,22 
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 Compound 1 was isolated as a bright pink solid with mp 218-220 ºC and 
demonstrated a molecular formula of C19H18NO6, as assigned from the HRESIMS ion peak at 
m/z 356.1136 [M+H]+ (calcd 356.1134). The UV spectrum displayed maximal absorption 
bands at max  224, 338, 371 and 389 nm and the IR spectrum revealed the presence of one or 
more hydroxy groups (3419 cm-1), a conjugated amide group (1649 cm-1), and an aromatic 
(1584 and 1504 cm-1) ring system, indicating the presence of an oxoprotoberberine 
nucleus.23,24 The 1H NMR spectrum (Table 1) displayed resonances for a chelated hydroxy 
group (δH 13.17, 1H, br s), two ortho-coupled aromatic protons [δH 7.25 (1H, d, J = 8.4 Hz) 
and 7.02 (1H, d, J = 8.4 Hz)], a singlet aromatic proton (δH 7.12), a singlet olefinic proton (δH 
7.24), a set of coupled methylene protons [δH 4.24 (2H, t, J = 6.2 Hz) and 2.96 (2H, t, J = 6.2 
Hz)], and two methoxy groups at δH 3.95 and 3.84 (each, 3H, s). Compound 1 showed 
resonances for an amide carbonyl (δC 165.8), ten quaternary carbons (δC 152.9, 148.1, 147.5, 
143.2, 137.7, 135.0, 130.6, 126.1, 116.2 and 111.6), four methines (δC 123.1, 116.7, 104.9 
and 100.7), two methylenes (δC 39.4 and 21.4), and two methoxy groups (δC 60.8 and 56.2) in 
the 13C NMR and DEPT spectra (Table 1). The chelated hydroxy proton at δH 13.17 was 
located at C-9 (δC 148.1) due to being hydrogen bonded to the amide carbonyl carbon at C-8 
(δC 165.8). Two ortho-coupled aromatic protons at δH 7.25 and 7.02 were assigned to H-11/δC 
123.1 and H-12/δC 116.7, respectively, on the basis of the correlations of H-11 with C-9, C-
10 (δC 143.2) and C-12a (δC 130.6) and H-12 with C-8a (δC 111.6), C-10 and C-13 (δC 104.9) 
in the HMBC spectrum. The olefinic proton resonating at δH 7.24 was assigned as H-13 based 
on HMQC and HMBC correlations. These data together with the carbon chemical shifts of C-
9 and C-10 confirmed the presence of the hydroxy groups at C-9 and C-10. The low field 
methylene protons at δH 4.24 were assigned to H-6 due to the inductive effect of the N atom 
of the amide group and HMBC correlations with C-4a (δC 116.2), C-5 (δC 21.4), C-8 (δC 
165.8), and C-13a (δC 135.0). The remaining coupled methylene protons at δH 2.96 were 
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attributed to H-5. The substituent at C-4 was identified as a hydroxy group from its 13C NMR 
chemical shift (δC 147.5) and the HMBC correlation between H-5 with C-4. The two 
methoxy groups (δH 3.95 and 3.84) were located at C-2 (δC 152.9) and C-3 (δC 137.7), 
respectively, on the basis of HMBC correlations and their 13C NMR chemical shifts. The 
resonance for C-3 appeared at a high field (δC 137.7) due to the occurrence of two ortho 
oxygen substituents. The singlet aromatic proton resonance at δH 7.12 was assigned to H-1, 
on the basis of the HMBC correlations with C-2, C-3, and C-13a. Consequently, compound 1 
(miliusacunine A) was elucidated as 8-oxo-4,9,10-trihydroxy-2,3-dimethoxy-5,6-
dihydroberberine. 
 Compound 2 was obtained as a yellow solid (mp 217-218 C), which showed a 
[M+Na]+ ion at m/z 392.1112 in the HRESIMS, consistent with a molecular formula of 
C20H19NO6Na (calcd 392.1110). The spectroscopic data of compound 2 was similar to those 
of 1, except that compound 2 displayed an additional methoxy group resonance at δH 3.89. 
This methoxy group was located at C-4 (δC 151.1) based on the HMBC correlation with C-4. 
This assignment was further supported from the HMBC correlation between the methylene 
protons H-5 [δH 2.98 (t, J = 6.2 Hz)] with C-4. Therefore, compound 2 (miliusacunine B) was 
characterized as the 4-O-methyl ether of compound 1. 
 Compound 3 was obtained as a reddish brown gum, and its UV and IR data were 
similar to those of compound 1. Its 1H NMR and 13C NMR data indicated one of the methoxy 
groups in 3 to be located to a different position as that found in 1. The methoxy group 
resonance at δH 3.91 showed a HMBC correlation to C-4 (δC 143.8), while a HMBC 
correlation between the methylene protons H-5 [δH 2.98 (t, J = 5.6 Hz)] and C-4 was also 
observed. This indicated that the methoxy group is located at C-4. The other methoxy group 
(δH 4.00) was located at C-2 (δC 147.2), according to its HMBC correlation with C-2. The 
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substituent at C-3 was assigned as a hydroxy group by the relative high field 13C NMR 
chemical shift of C-3 at δC 139.8 due to its two ortho oxygen substituents. The locations of 
the methoxy and hydroxy groups attached at C-2 and C-3, respectively, were also confirmed 
by the HMBC correlations between the aromatic proton H-1 (δH 7.04/δC 103.0) and C-2 and 
C-3. Thus, the structure of 3 (miliusacunine C) was assigned as 8-oxo-3,9,10-trihydroxy-2,4-
dimethoxy-5,6-dihydroberberine. 
 Compound 4 was obtained as a brownish yellow gum and gave a specific rotation of 
[α]28D
 –175 (c 0.07, MeOH). The 1H NMR spectroscopic data of 4 were similar to those of 3. 
The main differences found were the additional methine 1H NMR signal [δH 4.83 (1H, br d, J 
= 13.2 Hz)], which was coupled to two diastereotopic methylene protons [δH 3.14 (1H, br d, J 
= 15.3 Hz) and 2.89 (1H, br t, J = 15.3 Hz)] for compound 4. This methylene group was 
situated at C-13 (δC 37.1) by the observation of its HMQC cross peak and the HMBC 
correlations of H-13 to C-1a (δC 126.7), C-8a (δC 111.2), C-12 (δC 116.8), C-12a (δC 128.2) 
and C-13a (δC 55.7) and between the aromatic proton H-12 [δH 6.61 (d, J = 8.0 Hz)] and C-
13. The methine proton (δH 4.83) was located at C-13a (δC 55.7) from the correlation between 
the singlet aromatic proton at δH 6.52 (H-1) and C-13a in the HMBC spectrum. Therefore, the 
structure of 4 (miliusacunine D) was analyzed as (–)-(S)-8-oxo-3,9,10-trihydroxy-2,4-
dimethoxy-5,6,13,13a-tetrahydroberberine. Its configuration was assigned based on the sign 
of its specific rotation when compared to that of the related compound, (S)-(–)-2,3-
dimethoxy-8-oxoberbine, [α]D
 –413.8 (c 0.36, CHCl3),
25 for which the structure was assigned 
using X-ray crystallography. 
Compound 5 was obtained as a yellow gum with a specific rotation of [α]28D
 –93 (c 
0.02, MeOH). Comparison of its NMR data with those of 4 showed the presence of an 
additional resonance for a methoxy group (δH 3.89) in 5, which was located at C-3 on the 
basis of its HMBC correlation with C-3 (δC 140.9). The aromatic proton H-1 (δH 6.53) 
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correlated to C-3 in the HMBC spectrum, further supporting the location of the additional 
methoxy group. Thus, the structure of 5 (miliusacunine E) was assigned as the (–)-(S)-3-O-
methyl ether of compound 4. 
All of the isolated compounds were evaluated for their cytotoxic activities against the 
KB (human oral epidermoid cancer cell line) and a non-cancerous cell line (African green 
monkey kidney cell line) as well as for antimalarial activity against the Plasmodium 
falciparum strains, TM4 and K1 (multidrug resistant strain) (Table 3). Compound 9 exhibited 
cytotoxic activity against the KB cell line with an IC50 value of 10.2  0.1 μM and showed 
antimalarial activity against both strains with IC50 values of 11.1  2.0 and 9.1  1.0 μM, 
respectively. However this compound was relatively cytotoxic with an IC50 value of 13.5  
0.5 μM against the Vero cell line. In earlier work, compound 9 was isolated from the leaves, 
twigs and flowers of Miliusa sinensis, and was demonstrated as being cytotoxic to the human 
oral epidermoid carcinoma (KB), human prostate carcinoma (LNCaP), human lung 
carcinoma (Lu-1), human colon carcinoma (Col-2), and human umbilical vein endothelial 
(HUVEC) cell lines.26 Compounds 1-5, 8, and 11-13 displayed weaker antimalarial activity 
than compound 9, with the IC50 values ranging from 19.3-41.4 and 10.8-54.9 μM against the 
TM4 and K1 strains, respectively. None of these was cytotoxic for the Vero cell line. Among 
these, compound 1 showed antimalarial activity against the TM4 strain with an IC50 value of 
19.3  3.4 μM and compound 2 demonstrated significant activity against the K1 strain with 
an IC50 value of 10.8  4.1 μM. 
EXPERIMENTAL SECTION 
 General Experimental Procedures. Melting points were measured with a Sanyo 
Gallenkamp melting point apparatus and are uncorrected. Optical rotation values were 
determined on a Bellingham and Stanley APD440 polarimeter. The UV spectra were 
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recorded with a Perkin-Elmer UV-vis spectrophotometer, whereas the IR spectra were 
obtained using a Bruker Tensor FT-IR spectrophotometer. NMR spectroscopic data were 
obtained on a 400 MHz Bruker Ultra Shield FT-NMR and a 500 MHz Varian Unity INOVA 
NMR spectrometer. Chemical shifts are recorded in parts per million () in CDCl3 (H 7.26 
and C 77.2) and/or acetone-d6 (H 2.05 and C (CO) 206.2 and (CH3) 29.8, with TMS as an 
internal reference. Mass spectrometric data were obtained on a Micro TOF, Bruker Daltonics 
mass spectrometer. Thin-layer chromatography (TLC) was performed on silica gel 60 GF254 
(Merck). Column chromatography (CC) was performed on Sephadex LH-20, and silica gel 
(Merck) type 100 (63-200 m) and type 60 (5-40 m for quick column chromatography; 
QCC). All solvents for extraction and chromatography were routinely distilled prior to use. 
 Plant Material. The leaves and twigs of M. cuneata were collected at Doi Tung, Chiang 
Rai Province, Thailand in September 2013. The plant was identified by Mr. James F. 
Maxwell from the CMUB Herbarium, Chiang Mai University, where a voucher specimen has 
been deposited (specimen no. Martin van de Bult 1328). 
 Extraction and Isolation. The air-dried leaves (0.60 kg) of M. cuneata were extracted 
with acetone (15 L) over a period of three days for three times at room temperature. Removal 
of the solvent under reduced pressure provided an acetone extract (88.41 g) as a dark green 
gum. The crude extract was separated by QCC over silica gel, eluting with a gradient of 
hexanes and acetone (1:0 to 2:3), to give seven fractions (L1-L7). Fraction L2 (603.1 mg) 
was separated over Sephadex LH-20 with CH2Cl2-MeOH (1:4) to afford two subfractions 
(L2A and L2B), and the latter subfraction (31.6 mg) was fractionated further over Sephadex 
LH-20 with MeOH to provide three subfractions (L2B1-L2B3). The second subfraction (7.0 
mg) was purified by CC over silica gel using EtOAc-hexanes (1:9) as mobile phase to afford 
compound 6 (2.5 mg) as a brownish yellow solid, mp 181-183 C, lit. 182-183 C.16 Fraction 
L4 (1.30 g) was washed with MeOH and then hexanes, and the remaining solid was dried 
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under a vacuum to give compound 7 (140 mg) as a yellow solid, mp 173-174 C, lit. 171-172 
C.27 Separation of fraction L5 (10.73 g) by QCC over silica gel, with gradient elution using 
CH2Cl2-MeOH (1:0 to 9:1), gave five subfractions (L5A-L5E). Purification of subfraction 
L5B (20.0 mg) over Sephadex LH-20 with MeOH gave compound 5 (1.3 mg) as a yellow 
viscous oil and 2 (9.7 mg) as a yellow solid, respectively. Subfraction L5D (402.5 mg) was 
separated over Sephadex LH-20 with MeOH to produce three subfractions (L5D1-L5D3). 
Subfraction L5D2 (286.5 mg) was further purified by CC with acetone-hexanes (3:7) to yield 
compound 9 (149.4 mg) as a yellow viscous oil. Fraction L6 (7.82 g) was separated over 
silica gel by QCC with a gradient of CH2Cl2-MeOH (1:0 to 9:1) to afford three subfractions 
(L6A-L6C). Subfraction L6B (408.2 mg) was further separated over Sephadex LH-20 with 
MeOH to provide four additional subfractions (L6B1-L6B4). The second subfraction, L6B2 
(18.6 mg) was further purified over Sephadex LH-20 with MeOH to afford compound 4 (4.4 
mg) as a brownish yellow gum. Subfraction L6B4 (28.0 mg) was further separated by CC 
over silica gel with EtOAc-hexanes (3:7) to provide compound 1 (8.1 mg) as a bright pink 
solid. Fraction L7 (5.96 g) was separated over silica gel by QCC with a gradient of CH2Cl2-
MeOH (1:0 to 9:1) to afford three subfractions (L7A-L7C). Subfraction L7B (111.4 mg) was 
separated over Sephadex LH-20 with MeOH to obtain compounds 8 (10.1 mg) as a yellow 
gum and 3 (3.7 mg) as a brownish red gum. Subfraction L7B2 (20.3 mg) was further purified 
by CC over silica gel using EtOAc-hexanes (3:2) as mobile phase to afford compound 10 (2.8 
mg) as a yellow viscous oil. 
 The air-dried twigs (2.21 kg) of M. cuneata were macerated with acetone (15 L) over 
a period of three days (three times) at room temperature. The combined extracts were 
evaporated under reduced pressure to afford an acetone extract (35.0 g) as a dark brown gum. 
The crude extract was separated by QCC over silica gel and eluted with a gradient of 
hexanes-CH2Cl2-MeOH (1:0:0 to 0:4:1) to give nine fractions (T1-T9). Fraction T2 (860.0 
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mg) was separated by CC over silica gel eluting with CH2Cl2 to give three subfractions (T2A-
T2C). Subfraction T2B (46.0 mg) was purified over Sephadex LH-20 with MeOH to provide 
compound 6 (1.1 mg). Fraction T4 (2.79 g) was fractionated by QCC using EtOAc-hexanes 
(3:7 to 1:1) for elution to give three subfractions (T4A-T4C). Subfraction T4B (149.2 mg) 
was further purified by CC with CH2Cl2 to provide compound 7 (40.0 mg). Fraction T6 
(556.3 mg) was purified over Sephadex LH-20 with MeOH to afford compound 11 as a 
brownish red gum (1.2 mg). Fraction T8 (1.25 g) was separated over Sephadex LH-20 with 
MeOH to provide three subfractions (T8A-T8C). Subfraction T8B (425.2 mg) was purified 
by CC with EtOAc-CH2Cl2 (9:1) to give compound 12 as an orange gum (17.7 mg). Fraction 
T9 (1.40 g) was separated over Sephadex LH-20 with MeOH to give three fractions (T9A-
T9C). Subfraction T9B (194.6 mg) was further fractionated by CC with acetone-hexanes 
(3:7) to yield three fractions (T9B1-T9B3). Separation of subfraction T9B2 (24.0 mg) over 
Sephadex LH-20 with MeOH provided compound 13 as an orange-yellow gum (2.7 mg). 
Purification of subfraction T9B3 (19.0 mg) over Sephadex LH-20 with MeOH furnished 
compound 14 (9.7 mg) as a white solid, with mp 247-249 C, lit. 248 C.22 
Miliusacunine A (1): bright pink solid; mp 218-220 C; UV (MeOH) max (log ε) 224 
(4.5), 338 (4.2), 371 (4.1), 389 (4.1) nm; IR (neat) max 3419, 1649, 1617, 1584, 1504, 1463, 
1278, 1126 cm-1; 1H and 13C NMR data, see Table 1; HRESIMS m/z 356.1136 [M+H]+, calcd 
for C19H18NO6, 356.1134. 
Miliusacunine B (2): yellow solid; mp 217-218 C; UV (MeOH) max (log ε) 224 
(4.6), 341 (4.2), 371 (4.2), 389 (4.1) nm; IR (neat) max 3388, 1648, 1586, 1494, 1461, 1280, 
1032 cm-1; 1H and 13C NMR data, see Table 1; HRESIMS m/z 392.1112 [M+Na]+, calcd for 
C20H19NO6Na, 392.1110. 
Miliusacunine C (3): brownish red gum; UV (MeOH) max (log ε) 225 (4.3), 340 
(4.0), 372 (3.9), 389 (3.9) nm; IR (neat) max 3421, 1648, 1611, 1583, 1502, 1463, 1278, 
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1126, 1093 cm-1; 1H and 13C NMR data, see Table 1; HRESIMS m/z 378.0958 [M+Na]+, 
calcd for C19H17NO6Na, 378.0954. 
Miliusacunine D (4): brownish yellow gum; [α]28D –175 (c 0.07, MeOH); UV 
(MeOH) max (log ε) 218 (4.5), 262 (4.0), 341 (3.8) nm; IR (neat) max 3421, 1636, 1615, 
1584, 1459, 1267, 1120, 1091 cm-1; 1H and 13C NMR data, see Table 2; HRESIMS m/z 
380.1104 [M+Na]+, calcd for C19H19NO6Na, 380.1110. 
Miliusacunine E (5): yellow viscous oil; [α]28D –93 (c 0.02, MeOH); UV (MeOH) 
max (log ε) 218 (4.4), 265 (3.8), 325 (3.5) nm; IR (neat) max 3421, 1635, 1590, 1459, 1271, 
1121, 1097, 1029 cm-1; 1H and 13C NMR data, see Table 2; HRESIMS m/z 372.1454 [M+H]+, 
calcd for C20H22NO6, 372.1447. 
 Cytotoxicity Assays. KB cells (human oral epidermal carcinoma cells) and normal Vero 
cells (kidney epithelial cells of the African green monkey, Cercopithecus aethiops)28 were 
obtained from the Bioassay Laboratory, BIOTEC, NSTDA, Pathumthani, Thailand. Vero 
cells were maintained and cultured in MEM/EBSS supplemented with heated fetal bovine 
serum (10%), NaHCO3 (2.2 g/L), and sodium pyruvate (1%). KB cells were cultured in 
DMEM/low glucose supplemented with heated fetal bovine serum (10%), NaHCO3 (3.7 g/L), 
and NEAA (1%). Cytotoxicity was evaluated using the sulforhodamine B (SRB) assay.29 
Ellipticine and doxorubicin were used as the standard compounds. 
 Antimalarial Assay. The in vitro antimalarial activity against two strains of Plasmodium 
falciparum (TM4, a wild-type chloroquine and antifolate-sensitive strain and K1, a 
multidrug-resistant strain) were obtained from Prof. S. Thaithong, Department of Biology, 
Faculty of Science, Chulalongkorn, Bangkok, Thailand. The parasites were maintained in 
human red blood cells in RPMI 1640 medium supplemented with HEPES (25 mM), sodium 
bicarbonate (0.2%), and human serum (8%) in a carbon dioxide (3%) incubator maintained at 
37C. The test samples were made up in DMSO solution (25 µL, diluted in the culture 
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medium) and placed in triplicate in a 96-well plate where parasitized erythrocytes (200 µL) 
with a cell suspension (1.5%) of parasitemia (0.5-1%) were then added to the wells. The 
culture was incubated (18-20 h). The antiplasmodial activity testing was carried out using the 
Microdilution Radioisotope Technique as described by Yuthavong et al.30 Chloroquine, 
cycloguanil, and pyrimethamine were used as reference substances.31 Human erythrocytes 
and serum were obtained from donors after providing informed consent, following a protocol 
approved by the NSTDA Ethics Committee for Human Research, document no. 0007/2557. 
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Table 1. NMR ((1H 400 MHz) and 13C (100 MHz)) Data of Miliusacunines A and B (1 and 2) in Acetone-d6 and Miliusacunine C (3) in CDCl3 
position 
1  2  3 
C, type H, (J in Hz) HMBCa    C, type H, (J in Hz) HMBCa   C, type H, (J in Hz) HMBCa  
1 100.7, CH 7.12, s 1a, 2, 3, 4a, 13a  105.3, CH 7.34, s 1a, 2, 3, 4a, 13a  103.0, CH 7.04, s 2, 3, 4a, 13a 
1a 126.1, C   126.3, C    121.5, C   
2 152.9, C   154.0, C    147.2, C   
3 137.7, C   144.1, C    139.8, C   
4 147.5, C   151.1, C    143.8, C   
4a 116.2, C   122.5, C    122.1, C   
5 21.4, CH2 2.96, t (6.2) 1a, 4, 4a, 6  22.0, CH2 2.98, t (6.2) 1a, 4, 4a, 6  21.6, CH2 2.98, t (5.6) 1a, 4, 4a, 6 
6 39.4, CH2 4.24, t (6.2) 4a, 5, 8, 13a  39.7, CH2 4.23, t (6.2) 4a, 5, 8, 13a  39.0, CH2 4.25, t (5.6) 4a, 5, 8, 13a 
8 165.8, C   166.1b, C    165.0, C   
8a 111.6, C   111.9, C    109.9, C   
9 148.1, C   148.3b, C    146.8, C   
10 143.2, C   143.4, C    141.8, C   
11 123.1, CH 7.25, d (8.4) 9, 10, 12a  122.5, CH 7.26, d (8.4) 9, 10, 12a  121.6, CH 7.28, d (8.2) 9, 10, 12a 
12 116.7, CH 7.02, d (8.4) 8a, 10, 11, 12a, 13  117.0, CH 7.03, d (8.4) 8a, 10,11, 13  116.0, CH 6.97, d (8.2) 8a, 10, 13 
12a 130.6, C   130.8, C    130.2, C   
13 104.9, CH 7.24, s 1a, 8a, 12, 12a, 13a  105.2, CH 7.25, s 1a, 8a, 12, 13a  103.8, CH 6.86, s 1a, 8a, 11, 13a 
13a 135.0, C   134.7, C    134.7, C   
OCH3 (2) 56.2, CH3 3.95, s 2  56.6, CH3 3.95, s 2  56.7, CH3 4.00, s 2 
OCH3 (3) 60.8, CH3 3.84, s 3  61.3, CH3 3.88, s 3      
OCH3 (4)     61.1, CH3 3.89, s 4  61.0, CH3 3.91, s 4 
OH (9)   13.17, br s    13.15, br s       
aHMBC correlations are from proton(s) stated to the indicated carbon. 
bObserved from the HMBC spectrum. 
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Table 2. NMR ((1H 400 MHz) and 13C (100 MHz)) Data of Miliusacunines D and E (4 and 5) in 
CDCl3 
position 
4  5 
C, type H, (J in Hz) HMBCa    C, type H, (J in Hz) HMBCa  
1 103.8, CH 6.52, s 
1a, 2, 3, 4a, 
13a 
 104.9, CH 6.53, s 1a, 2, 3, 4a, 13a 
1a 126.7, C    131.1, C   
2 146.8, C    152.7, C   
3 137.3, C    140.9c, C   
4 144.3, C    151.0, C   
4a 121.3, C    121.4, C   
5 23.0, CH2 3.05, br d (15.7) 1a, 4, 4a, 6  23.0, CH2 3.03, br d (16.2) 1a, 4a, 6 
   2.70, m  1a, 4, 4a, 6    2.70, m 1a, 4, 4a, 6 
6 38.0, CH2 4.88, br d (13.2) 4a, 5, 8, 13a  38.2, CH2 4.87, br d (13.0) 4a, 5, 13a 
   2.86, br d (14.1) 4a, 5, 13a    2.85, br d (12.2) 4a, 5, 13a 
8 168.5, C    168.6, C   
8a 111.2, C    111.3, C   
9 148.6, C    148.7, C   
10 143.9, C    144.1, C   
11 118.2, CH 6.99, d (8.0) 9, 10, 12a  118.4, CH 6.99, d (7.7) 9, 10, 12a 
12 116.8, CH 6.61, d (8.0) 8a, 10, 11, 13  116.9, CH 6.61, d (7.7) 8a, 10, 11, 13 
12a 128.2, C    128.2, C   
13 37.1, CH2 3.14, br d (15.3)
b 1a, 8a, 12,   37.1, CH2 3.15, br d (15.2)
b 8a, 12, 12a, 13a 
    12a, 13a      
   2.89, br t (15.3)b 1a, 8a, 11,     2.91, br t (15.2)b 1a, 8a, 11, 12, 12a,  
    12, 12a, 13a     13a 
13a 55.7, CH 4.83, br d (13.2)b 1, 1a, 4a, 13  55.9, CH 4.82, br d (13.5)b 1, 1a, 4a, 13 
OCH3 (2) 56.4, CH3 3.92, s 2  56.4, CH3 3.92, s 2 
OCH3 (3)      61.0, CH3 3.89, s 3 
OCH3 (4) 60.6, CH3 3.89, s 4  61.1, CH3 3.89, s 4 
OH (9)   12.75, br s     12.74, br s  
OH (10)   5.59, br s       
aHMBC correlations are from proton(s) stated to the indicated carbon. 
bSignal partially obscured. 
cObserved from the HMBC spectrum. 
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Table 3. Cytotoxic and Antimalarial Activities of Compounds 1-14 (IC50, µM) 
 
compound 
cytotoxic activity  
antimalarial activity against 
P. falciparum 
KB Vero cells  TM4 K1 
1 -a -a  19.3 ± 3.4 26.3 ± 9.6 
2 -a -a  25.6 ± 1.2 10.8 ± 4.1 
3 -a -a  41.4 ± 1.0 32.4 ± 10.0 
4 -a -a  38.1 ± 4.6 26.1 ± 13.9 
5                        -a -a  -a 29.1 ± 3.1 
6 -a -a  -a -a 
7 -a -a  -a -a 
8 -a -a  31.5 ± 18.3 27.9 ± 11.8 
9 10.2 ± 0.1 13.5 ± 0.5  11.1 ± 2.0 9.1 ± 1.0 
10 -a -a  -a -a 
11 -a -a  39.5 ± 6.5 12.4 ± 3.7 
12 -a -a  -a 54.9 ± 5.9 
13 -a -a  -a 23.8 ± 2.1 
14 -a -a  -a -a 
doxorubicinb 1.0     
ellipticineb  0.4    
chloroquinec    0.03 0.3  0.04 
cycloguanilc    0.04  0.01 3.2  0.8 
pyrimethaminec    0.08  0.01 31.0  8.4 
aInactive at IC50 > 47.8 µM. 
bPositive control for cytotoxic assay.  
cReference drugs for antiplasmodial assays. 
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